Current clinical application of dantrolene sodium
Anesthesia and Pain Medicine · 31.07.2023 · 18 (3) · 220-232
DOI: 10.17085/apm.22260 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Anesthesia and Pain Medicine, erschienen am 31.07.2023. Verfasst von Hong Seuk Yang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology and Pain Medicine, Daejeon Eulji Medical Center, Eulji University, School of Medicine, Daejeon, Korea. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 108 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Dantrolene sodium (DS) was first introduced as an oral antispasmodic drug. However, in 1975, DS was demonstrated to be effective for managing malignant hyperthermia (MH) and was adopted as the primary therapeutic drug after intravenous administration. However, it is difficult to administer DS intravenously to manage MH. MH is life-threatening, pharmacogenomically related, and induced by depolarizing neuromuscular blocking agents or inhalational anesthetics. All anesthesiologists should know the pharmacology of DS. DS suppresses Ca2+ release from ryanodine receptors (RyRs). RyRs are expressed in various tissues, although their distribution differs among subtypes. The anatomical and physiological functions of RyRs have also been demonstrated as effective therapeutic drugs for cardiac arrhythmias, Alzheimer’s disease, and other RyR-related diseases. Recently, a new formulation was introduced that enhanced the hydrophilicity of the lipophilic DS. The authors summarize the pharmacological properties of DS and comment on its indications, contraindications, adverse effects, and interactions with other drugs by reviewing reference articles.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Anesthesiology and Pain Medicine, Daejeon Eulji Medical Center, Eulji University, School of Medicine, Daejeon, Korea.
- Department of Anesthesiology and Pain Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
- Department of Anesthesiology and Pain Medicine, Dongguk University Ilsan Hospital, Dongguk University, Goyang, Korea.
- Department of Anesthesiology and Pain Medicine, Konyang University Hopsital, Konyang University, College of Medicine, Daejeon, Korea.
- Department of Anesthesiology and Pain Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon, Korea.
- Department of Anesthesia, Analgesia and lntensive Care lVedicine, Bangabandhu Sheikh Mujib Medical University Dhaka, Bangladesh.
Zitieren
APA
Yang, H. S., Choi, J. M., In, J., Sung, T. Y., Kim, Y. B., & Sultana, S. (2023). Current clinical application of dantrolene sodium. Anesthesia and Pain Medicine, 18(3), 220-232. https://doi.org/10.17085/apm.22260
Vancouver
Yang HS, Choi JM, In J, Sung TY, Kim YB, Sultana S. Current clinical application of dantrolene sodium. Anesthesia and Pain Medicine. 2023;18(3):220-232. doi:10.17085/apm.22260
BibTeX
@article{Yang2023,
author = {Yang, Hong Seuk and Choi, Jae Moon and In, Junyong and Sung, Tae-Yun and Kim, Yong Beom and Sultana, Shofina},
title = {Current clinical application of dantrolene sodium},
journal = {Anesthesia and Pain Medicine},
year = {2023},
volume = {18},
number = {3},
pages = {220--232},
doi = {10.17085/apm.22260}
}
EUVIMED